Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 7/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340212 | 0.91 | DPP4 (0.39) | ALDH1A1DPP4DPP8ALPLDPP9 | |
| SCHEMBL339703 | 0.80 | P2RX7 (0.45) | CNR1USP2 | |
| SCHEMBL338577 | 0.79 | GSK3B (0.39) | ALDH1A1DPP4DPP8DPP9 | |
| SCHEMBL339881 | 0.79 | GSK3B (0.36) | CNR1DPP4DPP8DPP9 | |
| SCHEMBL1911445 | 0.78 | P2RX7 (0.38) | ALDH1A1LMNACNR1CNR2DPP4 | |
| SCHEMBL1912414 | 0.78 | P2RX7 (0.38) | ALDH1A1LMNACNR1CNR2DPP4 | |
| SCHEMBL338848 | 0.78 | P2RX7 (0.38) | ALDH1A1LMNACNR1CNR2DPP4 | |
| SCHEMBL339320 | 0.78 | DPP4 (0.41) | LMNADPP4DPP8DPP9HPGD | |
| SCHEMBL339777 | 0.78 | EPHX2 (0.38) | DPP4DPP8DPP9SLC2A2 | |
| SCHEMBL339260 | 0.75 | CHRM3 (0.33) | ALDH1A1LMNACNR1DPP4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-20120077787-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-03-29 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-8097617-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-01-17 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253689-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077787-A1 | ORGANIC COMPOUNDS | OAT, GPR119, OTC | ALDH1A1 480/4885LMNA 3629/4885CNR1 1923/4885 |
| US-20090253689-A1 | Organic Compounds | OAT, GPR119, OTC | ALDH1A1 480/4885LMNA 3629/4885CNR1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.